Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 18 Month Phase 2a Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)

Next Previous
Trial Profile

An 18 Month Phase 2a Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors IVERIC bio

Most Recent Events

  • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
  • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
  • 18 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top